Cefotaxime biochemist powder for solution for injection 1g vial 1 piece with rastv.amp.5ml

$3.44

Cefotaxime biochemist powder for solution for injection 1g vial 1 piece with rastv.amp.5ml

Quantity:

Description

Composition
Active substance:
1 vial contains: cefotaxime sodium salt – 500 mg or 1000 mg.
Product form:
Powders for injection.
Contraindications
Hypersensitivity to cefotaxime (including penicillin, other cephalosporins, carbapenems), children (intramuscular – 2.5 years when used as lidocaine solvent).
Carefully.
Neonatal period (for intravenous administration), chronic renal insufficiency, ulcerative colitis (including history).
Indications
Infectious-inflammatory diseases caused by susceptible to cefotaxime microorganisms: infections of the central nervous system (meningitis), respiratory tract and upper respiratory tract, urinary tract, bones, joints, skin and soft tissues (including infected wounds and burns), pelvic peritonitis , bacteremia, septicemia, intra-abdominal infections, endocarditis, Lyme disease, gonorrhea, and infections due to immune deficiency. Prevention of infections after surgery (including urology, obstetrics and gynecology, gastro-intestinal tract).
Interaction with other drugs
Pharmaceutically compatible with solutions of other antibiotics in the same syringe or dropper.
It increases the risk of bleeding in combination with antiplatelet agents, non-steroidal anti-inflammatory drugs.
The likelihood of kidney damage increases when concomitantly with an aminoglycoside, polymyxin B, and “loop” diuretics.
Drugs that block tubular secretion, increase the plasma concentrations of cefotaxime and slow down its excretion.
pharmachologic effect
Pharmacological group:
Antibacterials.
Pharmacodynamics:
III generation cephalosporin antibiotic for parenteral administration. Bactericidal effect, disrupting the synthesis of cell walls of microorganisms. It has a wide spectrum of action.
It is active against gram-positive and gram-negative microorganisms resistant to other antibiotics: Staphylococcus spp. (Including Staphylococcus aureus, including strains forming penicillinase), Staphylococcus epidermidis (except for Staphylococcus epidermidis and Staphylococcus aureus, methicillin-resistant), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus spp., Enterobacter spp., Escherichia coli, Borrelia burgdorferi, Haemophilus influenzae (including strains forming penicillinase), Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella spp. (Including Klebsiella pneumoniae), Morganella morganii, Neisseria meningitidis, Neisseria gonorrhoeae (including strains forming penicillinase), Acinetobacter spp., Corynebacterium diphtheriae, Erysipelothrix rhusiopathiae, Eubacterium spp., Propionibacterium spp., Clostridium spp. (Including Clostridium perfringens), Citrobacter spp., Proteus mirabilis, Proteus vulgaris, Providencia spp. (Including Providencia rettgeri), Serratia spp., Some strains of Pseudomonas aeruginosa, Bacteroides spp. (Including some strains of Bacteroides fragilis), Fusobacterium spp. (Including Fusobacterium nucleatum), Peptococcus spp., Peptostreptococcus spp. Most strains of Clostridium difficile – resistant. Resistant to most beta-lactamases of gram-positive and gram-negative microorganisms.
Pharmacokinetics:
After single intravenous injection at doses of 0.5 g, 1 g and 2 g of time to maximum concentration – 5 minutes, the maximum concentration of 39, 101.7 and 214 ug / ml, respectively. After intramuscular administration at doses of 0.5 and 1 g of time to maximum concentration – 0.5 hours and a maximum concentration of 11 and 21 micrograms / ml, respectively. Relationship to plasma proteins – 30-50%. Bioavailability – 90-95%. It creates therapeutic concentrations in most tissues (myocardium, bone, gall bladder, skin, soft tissue) and fluids (synovial, pericardial, pleural, sputum, bile, urine, cerebrospinal fluid) of the organism. The volume of distribution – 0.25 – 0.39 L / kg. The half-life – 1 hour at intravenous administration and 1 – 1.5 hours – intramuscular administration. Excreted by the kidneys – 20 – 36% in an unmodified form, the rest – in the form of metabolites (15 – 25% – in the form of a pharmacologically active dezatsetiltsefotaksima and 20 – 25% – in the form of inactive metabolites 2 – M2 and M3). In chronic renal insufficiency and in the elderly half-life increased by 2 times. The half-life in neonates – 0.75-1.5 hours in premature neonates (body weight less than 1500 g) was increased to 4.6 hours; children weighing more than 1500 g – 3.4 hours. In repeated intravenous dose of 1g every 6 hours for 14 days cumulation is not observed. It passes into breast milk.
Pregnancy and breast-feeding
Application of pregnancy is possible only in cases where the potential benefit to the mother outweighs the risk to the fetus. Adequate and well-controlled studies in pregnant women have not been conducted.
If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions: urticaria, chills and fever, rash, pruritus, bronchospasm, eosinophilia, malignant erythema multiforme (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), angioneurotic edema, anaphylactic shock.
From the nervous system: headache, dizziness, encephalopathy, movement disorders, convulsions.
From the urinary system: renal dysfunction, oliguria, interstitial nephritis.
From the digestive system: nausea, vomiting, diarrhea or constipation, bloating, abdominal pain, goiter, liver dysfunction, stomatitis, glossitis, pseudomembranous colitis, hepatitis, jaundice.
From the side of hematopoiesis: hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, hypocoagulation, agranulocytosis.
Cardio-vascular system: a potentially life-threatening arrhythmia following a rapid bolus into the central vein.
Laboratory parameters: azotemia, increased concentration of urea in the blood, increased activity of “liver” transaminases and alkaline phosphatase, hypercreatininemia, hyperbilirubinemia, false positive Coombs test.
Other: superinfection (such as candida vaginitis).
Local reactions: phlebitis, pain along the vein, pain and infiltrate at the site of intramuscular administration.
Overdose
Symptoms: convulsions, encephalopathy (in the case of the administration of large doses, especially in patients with renal failure), tremor, increased neuromuscular excitability.
Treatment: symptomatic, maintaining vital functions. There is no specific antidote.
special instructions
In the first weeks of treatment may be pseudomembranous colitis manifested by severe prolonged diarrhea. At this stop taking the drug and prescribe appropriate therapy, including vancomycin or metronidazole.
Patients who had a history of allergic reaction to penicillin, may be sensitive to cephalosporin antibiotics.
In drug treatment, more than 10 days is necessary to monitor the number of blood cells. During treatment with cefotaxime may receive false-positive and false-positive Coombs reaction urine for glucose.
When applying odovremenno cephalosporin antibiotics and ethanol development disulfiramopodobnyh reactions, but in clinical studies of cefotaxime (claforan) was registered a similar effect when it is applied simultaneously with ethanol.
Effects on ability to drive vehicles and management mechanisms
During the period of treatment should refrain from road management and classes of potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In the dark place at a temperature not exceeding +25 ° C.
Dosing and Administration
Adults and children weighing 50 kg or more: in uncomplicated infections – intramuscularly or intravenously at 1 g every 12 hours; uncomplicated acute gonorrhea – intramuscular injection, 0.5 – 1 g once; at moderate infections – intramuscularly or intravenously, and 1 – 2 g every 8 hours; in sepsis – intravenous injection, 2 g every 6 – 8 hours, with life-threatening infections (meningitis) – intravenous injection, 2 grams every 4 hours maximum daily dose – 12 g. duration of treatment is determined individually.
For prevention of infection before surgery administered during induction of general anesthesia once one of administering repeated if necessary after 6 – 12 hours.
At caesarean section (at terminals overlay umbilical vein) – 1 g i.v., then at 6 and 12 hours after the first dose – in addition to 1 g
If creatinine clearance of 20 ml / min / 1.73 sq. m and less than the daily dose reduced by 2 times.
Premature and newborn up to 1 week – i.v. 50 mg / kg every 12 hours; aged 1 – 4 weeks – i.v. 50 mg / kg every 8 hours; children weighing up to 50 kg – intravenous or intramuscular injection of 50 – 180 mg / kg in 4 – 6 administrations. In severe infections, including meningitis, the daily dose is increased to 100 – 200 mg / kg, intramuscularly or intravenously, in 4 – 6 steps, the maximum daily dose – 12 g.
Terms preparation of injectable solutions: for intravenous injection as solvent is water for injection (1 g diluted in 4 ml of solvent); for intravenous infusion is used as solvent 0.9% chloride or 5% dextrose solution, a solution of sodium (1 gram diluted in 50 – 100 ml of solvent). Infusion duration – 50 – 60 minutes.
For intramuscular injection using water for injection or a 1% lidocaine solution (1 g diluted in 4 ml of solvent).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

PROMOMED RUS

There are no reviews yet.

Add your review